Abstract

Dulaglutide using once-2 weeks for dialysis type 2 diabetes patients in Japan

Author(s): Mari Koga* & Ishii Masao

Object: Dulaglitide is one of glucagon like peptide-1 receptor agonist. It is ususally used once- 1 week. The efficacy of drug is easy to remain in the patients with impaired renal function. We evaluate the efficiency of once-2 weeks dulaglitide after switching from once-1 week injection in 4 out patients of type 2 diabetes undergoing hemodialysis in Japan. Methods: After changing dulaglutide treatment from once-1 week to once-2 weeks in dialysis type 2 diabetes patients, the effect of glycemic control was evaluated by Glico albumin (GA). And mean blood glucose (mean BS), 24 h Area under the blood concentration-time curve (AUC), AUC>180 and the mean amplitude of glycemic excursions (MAGE) were evaluated by using continuous glucose monitoring (CGM). Results: GA was decrease from 20.3 ± 0.47% to 19.3 ± 0.47% in case 1, from 24.5 ± 0.79% to 22.2 ± 2.18% in case 3, and from 20.3 ± 0.47% to 19.3 ± 0.47% in case 4 after changing of dulaglutide injection from once-1 week to once-2 weeks. CGM was examined in case 4 and case 5. Mean BS, 24 h AUC and AUC>180 were improved in case 4. MAGE and AUC>180 were improved by dulaglutide injection once-1 week to once-2 weeks in case 5. Conclusion: Once-2 weeks dulaglutide treatment is useful for glycemic control in dialysis type2 diabetic patients.


PDF